Compare PLUR & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLUR | MDBH |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 29.0M |
| IPO Year | 2001 | 2022 |
| Metric | PLUR | MDBH |
|---|---|---|
| Price | $2.03 | $3.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 10.8K | 3.8K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,336,000.00 | N/A |
| Revenue This Year | $97.38 | N/A |
| Revenue Next Year | $293.97 | N/A |
| P/E Ratio | ★ N/A | $4.06 |
| Revenue Growth | ★ 309.82 | N/A |
| 52 Week Low | $2.00 | $2.45 |
| 52 Week High | $5.96 | $5.50 |
| Indicator | PLUR | MDBH |
|---|---|---|
| Relative Strength Index (RSI) | 32.49 | 48.30 |
| Support Level | N/A | $2.85 |
| Resistance Level | $2.58 | $3.83 |
| Average True Range (ATR) | 0.13 | 0.20 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 7.12 | 65.06 |
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.